

ACAA, wherein each A and C is as independently defined in claim 1;

Gly_p, wherein p is an integer of from 0 to 10; and

Ala_q, wherein q is an integer of from 0 to 10.

C1
Sub F1
5. (Amended) The purified peptide according to claim 1, wherein R¹-R² or R³, or both, do not comprise an amino acid selected from the group consisting of A, B and C as defined in claim 1.

6. (Amended) The purified peptide according to claim 1, wherein motifs (A-C-B-A) are present in said peptide in a greater amount than motifs (A-B-C-A).

Aut 12/1
8. (Twice amended) The peptide BP 1, having SEQ ID NO: 1.

9. (Twice amended) The peptide BP 2, having SEQ ID NO: 2.

C2
Sub 95
10. (Twice amended) The peptide BP 2.3, having SEQ ID NO: 3.


11. (Twice amended) The peptide BP 2.4, having SEQ ID NO: 4.

12. (Twice amended) The peptide BP 2.5, having SEQ ID NO: 5.

Sub F1
13. (Twice Amended) The purified peptide according to claim 1, wherein the peptide is coupled to a non-peptide carrier, radioactive tag or fluorescent label.

C3
14. (Amended) A fusion peptide comprising the peptide of claim 1 coupled to a second peptide selected from the group consisting of peptide carriers and diagnostic peptides.

Sub D6
15. (Amended) A pharmaceutical composition comprising a peptide according to claim 1 as active component for treating topical and systemic microbial or parasite infection, or both, and a pharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.



wherein

R^1 , R^2 , and R^3 each are an amino acid,

x is an integer ≥ 0 ,

y is an integer ≥ 0 ,

each A is an amino acid independently selected from the group consisting of Lys, Arg and His,

each B is an amino acid independently selected from the group consisting of Phe, Trp and Tyr,

each C is an amino acid independently selected from the group consisting of Leu, Ile, Val and Ala,

m is an integer of from 2 to 8,

n is an integer of from 1 to 3, and

wherein one or more of the sequence motifs (A-B-C-A) may have the retro orientation

(A-C-B-A).

2. (Amended) The purified peptide according to claim 1, wherein x and y are each an integer of from 0 to 15.

3. (Amended) The purified peptide according to claim 1, wherein x and y are each an integer of from 1 to 10.

4. (Amended) The purified peptide according to claim 1, wherein R^1 is selected from the group consisting of:

Sub
F1
21. (Amended) A pharmaceutical composition comprising a mixture of at least two peptides according to claim 1 as active components for treating topical and systemic microbial or parasite infections, or both, and a pharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.

C4
22. (Amended) The pharmaceutical composition according to claim 15, further comprising an antibiotic selected from the group consisting of penicillins, cephalosporins, β -lactams, aminoglycosides, quinolones, tetracyclines, macrolides, glycopeptides or lipopeptides, hydrophobic antibiotics, ribosome inhibitors or antibiotics having a large lipid-like lactone ring.

21 23. (Amended) The pharmaceutical composition according to claim 15, wherein the infection is caused by a parasite.

Sub
F1
C5
28. (Amended) A method for treatment of microbial infection in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a peptide according to claim 1.

25 29. (Amended) The method according to claim 28, wherein said treatment is applied after trauma or suspected infection has occurred.

Please add the following new claims:

Sub
F1
C6
40. A pharmaceutical composition for treating bacterial inflammation comprising a therapeutically effective amount of a purified peptide according to claim 1, and a pharmaceutically acceptable carrier.

41. A pharmaceutical composition for treating bacterial septic shock comprising a therapeutically effective amount of a peptide according to claim 1, and a pharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.

42. The purified peptide according to claim 1, wherein x and y are each 0.

43. The pharmaceutical composition according to claim 21, wherein said parasite is selected from the group consisting of a parasite causing malaria and a parasite causing

Trypanosomiosis.

44. A method for treatment of microbial infection in a human, comprising administering to a human in need of such treatment a therapeutically effective amount of a peptide according to claim 1.

45. A method for inhibiting the growth of a microbe comprising the step of contacting a microbe with an effective amount of a purified peptide according to claim 1.

46. A method for inhibiting the growth of a Gram-negative bacterium comprising the step of contacting a Gram-negative bacterium with an effective amount of a purified peptide according to claim 1.

47. A method for inhibiting the growth of a Gram-positive bacterium comprising the step of contacting a Gram-positive bacterium with an effective amount of a purified peptide according to claim 1.